Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Preventive agent or therapeutic agent for disease caused by abnormal bone metabolism

A technology for abnormal bone metabolism and preventive medicine, which can be used in bone diseases, anti-tumor drugs, drug combinations, etc., and can solve problems such as difficult to find better treatment methods or preventive methods.

Inactive Publication Date: 2010-08-18
TEIJIN PHARMA CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

From this example, it is not easy to find a better treatment or prevention method using existing or new osteoporosis treatment drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preventive agent or therapeutic agent for disease caused by abnormal bone metabolism
  • Preventive agent or therapeutic agent for disease caused by abnormal bone metabolism
  • Preventive agent or therapeutic agent for disease caused by abnormal bone metabolism

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] [Example 1] N-hydroxyl-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentyloxy}-benzamidine Effects of and risedronic acid on the formation of osteoclast-like cells

[0043] As for the cells from mouse bone marrow, the bone marrow of mouse femur and tibia was collected, and then red blood cells were removed by conventional methods, and 4×10 5 The density of cells / well was seeded in a 96-well plate. After culturing overnight, 1α, 25-dihydroxyvitamin D3 (hereinafter referred to as 1α, 25(OH) 2 D. 3 ) medium to make 1α, 25(OH) 2 D. 3 reach 10 -9 Concentration of M, in 1α, 25(OH) 2 D. 3 In the presence of 7 days, multinucleated osteoclast-like cells were formed. As the medium, αMEM medium supplemented with 10% fetal calf serum (hereinafter referred to as 10% FCS-αMEM) was used. Addition of 1α,25(OH) to cells from mouse bone marrow 2 D. 3 , to the cell culture system from mouse bone marrow: add solvent only (comparative example 1-1), add N-hydroxy-4-{5-[4...

Embodiment 2

[0058] [Example 2] N-hydroxyl-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentyloxy}-benzamidine Study on the Effect of And Risedronic Acid on Osteoclast Formation

[0059] In addition to making N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentyloxy}-benzamidine in the medium Concentration in 10 -6 Except for M, the same experiment as in Example 1 was performed, and the following groups were set.

Embodiment 3

[0071] [Example 3] N-hydroxyl-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentyloxy}-benzamidine Study on the effect of and clodronic acid on the formation of osteoclasts

[0072] In embodiment 1, except making clodronic acid in comparative example, embodiment with 10 -5 The concentration of M interacts with the cells to replace risedronic acid at 3×10 -7 Except for the concentration of M and the effect on cells, the same experiment as in Example 1 was carried out, and the following groups were set.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

It is intended to provide a preventive agent or a therapeutic agent for a disease caused by abnormal bone metabolism, particularly for osteoporosis, which is more effective than ever before. By combined application of N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)-phenoxy]pentoxy}-benzamidine or a salt thereof and one or more compounds selected from the group consisting of etidronic acid, clodronic acid, pamidronic acid, tiludronic acid, risedronic acid, minodronic acid, ibandronic acid, zoledronic acid, and salts thereof, a higher bone resorption inhibitory action compared with the administration of a single compound is exhibited, and an excellent preventive effect and therapeutic effect for a disease caused by abnormal bone metabolism, particularly for osteoporosis can be obtained.

Description

technical field [0001] The present invention relates to a preventive or therapeutic drug for diseases caused by abnormal bone metabolism, in particular to a preventive or therapeutic drug for osteoporosis, in particular to a drug containing N-hydroxy-4-{5-[4-(5-iso Propyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentyloxy}-benzamidine or its salt and selected from etidronic acid, clodronic acid, pamidronic acid, alternative Diseases caused by abnormal bone metabolism, especially osteoporosis, in which one or more compounds of ludronic acid, risedronic acid, minodronic acid, ibandronic acid, zoledronic acid, and their salts are used as active ingredients prophylaxis or treatment of disease. Background technique [0002] N-hydroxyl-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentyloxy}- Benzamidine or a salt thereof has a bone resorption inhibiting effect and a bone formation promoting effect, and is expected as a therapeutic or preventive drug for osteoporosis. [0003...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/426A61K33/42A61P19/08
CPCA61K31/675A61K45/06A61K31/663A61K31/426A61P19/02A61P19/08A61P19/10A61P35/00A61K2300/00
Inventor 落合锐士西贺美幸高木健一郎东由明
Owner TEIJIN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com